67287-41-6

Downstream Products

• 1080523-25-6 7,8-dimethoxy-1,6-diphenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine 
• 1080523-28-9 6-(4-chlorophenyl)-7,8-dimethoxy-1-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine 
• 1080523-27-8 7,8-dimethoxy-1-phenyl-6-m-tolyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine 
• 1080523-29-0 6-(4-fluorophenyl)-7,8-dimethoxy-1-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine 
• 1080523-31-4 6-(furan-2-yl)-7,8-dimethoxy-1-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine 
• 73894-48-1 1-(7,8-Dimethoxy-1-phenyl-6-trifluoromethyl-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-2,2,2-trifluoro-ethanone 
• 73909-51-0 1-(7,8-Dihydroxy-1-phenyl-6-trifluoromethyl-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-2,2,2-trifluoro-ethanone 
• 74114-95-7 6-bromo-7,8-dihydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide 
• 73894-43-6 6-Bromo-7,8-dimethoxy-1-phenyl-3-trifluoro-acetyl-2,3,4,5-tetrahydro-1H-3-benzazepine 

Relevant academic research and scientific papers

6-Lower alkyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines

A series of 6-lower alkyl-7,8-dihydroxyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines having dopaminergic activity together with intermediates and processes for their preparation are disclosed.

6-HALO-3-LOWER ALKYL-7,8-DIHYDROXY-1-PHENYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINES

6-Halo-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines whose structures have a lower alkyl substituted at the 3 or N-position have potent and often specific anti-Parkinsonism activity by means of their central dopaminergic effect. The lead compound of the series is 6-chloro-3-methyl-1-phenyl-7,8-dihydroxy-2,3,4,5-tetrahydro-1H-3-benzazepin e as the base or its salts such as the hydrochloride, hydrobromide or methane sulfonate.

6-Carboxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds and use as dopaminergic agents

A group of 1-phenyl-3-benzazepines with structures characterized by having a carboxy derived substituent at position 6 which are dopaminergic agents or are intermediates for preparing other dopaminergic agents. Particular illustrative species include 6-carbomethoxy-7,8-dihydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine, 6-carboxy-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine and 6-carbomethoxy-7,8-dihydroxy-1-(4'-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine.

Benz-tetrasubstituted 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines

A group of 6,9-disubstituted-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines have dopaminergic activity. Examples of leading species of the invention are 6,9-dichloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine and 6,9-dichloro-7,8-dihydroxy-1-(p-hydroxy-phenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine in the form of an acid addition salt.

2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE-7,8-DIONES

Novel benzazepine derivatives having central and peripheral dopaminergic activity useful in treating Parkinson's and cardiovascular diseases. The compounds have additional use as intermediates for the synthesis of other benzazepines with similar useful properties. The 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-dione derivatives are particularly useful.